CCK2 receptor expression transforms non-tumorigenic human NCM356 colonic epithelial cells into tumor forming cells

Celia Chao, Xueliang Han, Kirk Ives, Jeseong Park, Andrey A. Kolokoltsov, Robert A. Davey, Mary P. Moyer, Mark Hellmich

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Expression of gastrin and cholecystokinin 2 (CCK2) receptor splice variants (CCK2R and CCK2i4svR) are upregulated in human colonic adenomas where they are thought to contribute to tumor growth and progression. To determine the effects of ectopic CCK2 receptor variant expression on colonic epithelial cell growth in vitro and in vivo, we employed the non-tumorigenic colonic epithelial cell line, NCM356. Receptor expression was induced using a retroviral expression vector containing cDNAs for either CCK2i4svR or CCK2R. RT-PCR and intracellular Ca2+ ([Ca2+]i) imaging of RIE/CCK2R cells treated with conditioned media (CM) from NCM356 revealed that NCM356 cells express gastrin mRNA and secrete endogenous, biologically active peptide. NCM356 cells expressing either CCK2R or CCK2i4svR (71 and 81 fmol/mg, respectively) grew faster in vitro, and exhibited an increase in basal levels of phosphorylated ERK (pERK), compared with vector. CCK2 receptor selective antagonist, YM022, partially inhibited the growth of both receptor-expressing NCM356 cells, but not the control cells. Inhibitors of mitogen activated protein kinase pathway (MEK/ERK) or protein kinase C (PKC) isozymes partially inhibited the elevated levels of basal pERK and in vitro growth of receptor-expressing cells. Vector-NCM356 cells did not form tumors in nude mice, whereas, either CCK2 receptor-expressing cells formed large tumors. Autocrine activation CCK2 receptor variants are sufficient to increase in vitro growth and tumorigenicity of non-transformed NCM356 colon epithelial cells through a pathway involving PKC and the MEK/ERK axis. These findings support the hypothesis that expression of gastrin and its receptors in human colonic adenomas contributes to tumor growth and progression.

Original languageEnglish
Pages (from-to)864-875
Number of pages12
JournalInternational Journal of Cancer
Volume126
Issue number4
DOIs
StatePublished - Feb 15 2010

Fingerprint

Cholecystokinin B Receptor
Epithelial Cells
Growth
Neoplasms
Adenoma
Protein Kinase C
MAP Kinase Kinase Kinases
Gastrin-Secreting Cells
Mitogen-Activated Protein Kinase Kinases
Gastrins
Conditioned Culture Medium
Mitogen-Activated Protein Kinases
Nude Mice
Isoenzymes
Colon
Complementary DNA
Cell Line
Polymerase Chain Reaction
Messenger RNA
Peptides

Keywords

  • CCK receptors
  • Colorectal tumorigenesis
  • Gastrin
  • NCM356 cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

CCK2 receptor expression transforms non-tumorigenic human NCM356 colonic epithelial cells into tumor forming cells. / Chao, Celia; Han, Xueliang; Ives, Kirk; Park, Jeseong; Kolokoltsov, Andrey A.; Davey, Robert A.; Moyer, Mary P.; Hellmich, Mark.

In: International Journal of Cancer, Vol. 126, No. 4, 15.02.2010, p. 864-875.

Research output: Contribution to journalArticle

Chao, Celia ; Han, Xueliang ; Ives, Kirk ; Park, Jeseong ; Kolokoltsov, Andrey A. ; Davey, Robert A. ; Moyer, Mary P. ; Hellmich, Mark. / CCK2 receptor expression transforms non-tumorigenic human NCM356 colonic epithelial cells into tumor forming cells. In: International Journal of Cancer. 2010 ; Vol. 126, No. 4. pp. 864-875.
@article{5bbd7f14cb06416aa9d93201ac53224f,
title = "CCK2 receptor expression transforms non-tumorigenic human NCM356 colonic epithelial cells into tumor forming cells",
abstract = "Expression of gastrin and cholecystokinin 2 (CCK2) receptor splice variants (CCK2R and CCK2i4svR) are upregulated in human colonic adenomas where they are thought to contribute to tumor growth and progression. To determine the effects of ectopic CCK2 receptor variant expression on colonic epithelial cell growth in vitro and in vivo, we employed the non-tumorigenic colonic epithelial cell line, NCM356. Receptor expression was induced using a retroviral expression vector containing cDNAs for either CCK2i4svR or CCK2R. RT-PCR and intracellular Ca2+ ([Ca2+]i) imaging of RIE/CCK2R cells treated with conditioned media (CM) from NCM356 revealed that NCM356 cells express gastrin mRNA and secrete endogenous, biologically active peptide. NCM356 cells expressing either CCK2R or CCK2i4svR (71 and 81 fmol/mg, respectively) grew faster in vitro, and exhibited an increase in basal levels of phosphorylated ERK (pERK), compared with vector. CCK2 receptor selective antagonist, YM022, partially inhibited the growth of both receptor-expressing NCM356 cells, but not the control cells. Inhibitors of mitogen activated protein kinase pathway (MEK/ERK) or protein kinase C (PKC) isozymes partially inhibited the elevated levels of basal pERK and in vitro growth of receptor-expressing cells. Vector-NCM356 cells did not form tumors in nude mice, whereas, either CCK2 receptor-expressing cells formed large tumors. Autocrine activation CCK2 receptor variants are sufficient to increase in vitro growth and tumorigenicity of non-transformed NCM356 colon epithelial cells through a pathway involving PKC and the MEK/ERK axis. These findings support the hypothesis that expression of gastrin and its receptors in human colonic adenomas contributes to tumor growth and progression.",
keywords = "CCK receptors, Colorectal tumorigenesis, Gastrin, NCM356 cells",
author = "Celia Chao and Xueliang Han and Kirk Ives and Jeseong Park and Kolokoltsov, {Andrey A.} and Davey, {Robert A.} and Moyer, {Mary P.} and Mark Hellmich",
year = "2010",
month = "2",
day = "15",
doi = "10.1002/ijc.24845",
language = "English",
volume = "126",
pages = "864--875",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - CCK2 receptor expression transforms non-tumorigenic human NCM356 colonic epithelial cells into tumor forming cells

AU - Chao, Celia

AU - Han, Xueliang

AU - Ives, Kirk

AU - Park, Jeseong

AU - Kolokoltsov, Andrey A.

AU - Davey, Robert A.

AU - Moyer, Mary P.

AU - Hellmich, Mark

PY - 2010/2/15

Y1 - 2010/2/15

N2 - Expression of gastrin and cholecystokinin 2 (CCK2) receptor splice variants (CCK2R and CCK2i4svR) are upregulated in human colonic adenomas where they are thought to contribute to tumor growth and progression. To determine the effects of ectopic CCK2 receptor variant expression on colonic epithelial cell growth in vitro and in vivo, we employed the non-tumorigenic colonic epithelial cell line, NCM356. Receptor expression was induced using a retroviral expression vector containing cDNAs for either CCK2i4svR or CCK2R. RT-PCR and intracellular Ca2+ ([Ca2+]i) imaging of RIE/CCK2R cells treated with conditioned media (CM) from NCM356 revealed that NCM356 cells express gastrin mRNA and secrete endogenous, biologically active peptide. NCM356 cells expressing either CCK2R or CCK2i4svR (71 and 81 fmol/mg, respectively) grew faster in vitro, and exhibited an increase in basal levels of phosphorylated ERK (pERK), compared with vector. CCK2 receptor selective antagonist, YM022, partially inhibited the growth of both receptor-expressing NCM356 cells, but not the control cells. Inhibitors of mitogen activated protein kinase pathway (MEK/ERK) or protein kinase C (PKC) isozymes partially inhibited the elevated levels of basal pERK and in vitro growth of receptor-expressing cells. Vector-NCM356 cells did not form tumors in nude mice, whereas, either CCK2 receptor-expressing cells formed large tumors. Autocrine activation CCK2 receptor variants are sufficient to increase in vitro growth and tumorigenicity of non-transformed NCM356 colon epithelial cells through a pathway involving PKC and the MEK/ERK axis. These findings support the hypothesis that expression of gastrin and its receptors in human colonic adenomas contributes to tumor growth and progression.

AB - Expression of gastrin and cholecystokinin 2 (CCK2) receptor splice variants (CCK2R and CCK2i4svR) are upregulated in human colonic adenomas where they are thought to contribute to tumor growth and progression. To determine the effects of ectopic CCK2 receptor variant expression on colonic epithelial cell growth in vitro and in vivo, we employed the non-tumorigenic colonic epithelial cell line, NCM356. Receptor expression was induced using a retroviral expression vector containing cDNAs for either CCK2i4svR or CCK2R. RT-PCR and intracellular Ca2+ ([Ca2+]i) imaging of RIE/CCK2R cells treated with conditioned media (CM) from NCM356 revealed that NCM356 cells express gastrin mRNA and secrete endogenous, biologically active peptide. NCM356 cells expressing either CCK2R or CCK2i4svR (71 and 81 fmol/mg, respectively) grew faster in vitro, and exhibited an increase in basal levels of phosphorylated ERK (pERK), compared with vector. CCK2 receptor selective antagonist, YM022, partially inhibited the growth of both receptor-expressing NCM356 cells, but not the control cells. Inhibitors of mitogen activated protein kinase pathway (MEK/ERK) or protein kinase C (PKC) isozymes partially inhibited the elevated levels of basal pERK and in vitro growth of receptor-expressing cells. Vector-NCM356 cells did not form tumors in nude mice, whereas, either CCK2 receptor-expressing cells formed large tumors. Autocrine activation CCK2 receptor variants are sufficient to increase in vitro growth and tumorigenicity of non-transformed NCM356 colon epithelial cells through a pathway involving PKC and the MEK/ERK axis. These findings support the hypothesis that expression of gastrin and its receptors in human colonic adenomas contributes to tumor growth and progression.

KW - CCK receptors

KW - Colorectal tumorigenesis

KW - Gastrin

KW - NCM356 cells

UR - http://www.scopus.com/inward/record.url?scp=74049157658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049157658&partnerID=8YFLogxK

U2 - 10.1002/ijc.24845

DO - 10.1002/ijc.24845

M3 - Article

C2 - 19697327

AN - SCOPUS:74049157658

VL - 126

SP - 864

EP - 875

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -